Publications by the researcher in collaboration with Alejandro Medina Herrera (19)

2024

  1. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease

    British Journal of Haematology

2023

  1. Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level

    Disease models & mechanisms, Vol. 16, Núm. 8

  2. Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories

    Frontiers in Oncology, Vol. 13

  3. Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future

    Cancers, Vol. 15, Núm. 14

2022

  1. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205

  2. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma

    Archives of pathology & laboratory medicine, Vol. 146, Núm. 7, pp. 862-871

  3. MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  4. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

2021

  1. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

    British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852

  2. Genetic complexity impacts the clinical outcome of follicular lymphoma patients

    Blood Cancer Journal

  3. Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping

    British Journal of Haematology, Vol. 195, Núm. 4, pp. 542-551

2020

  1. A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients

    Journal of Molecular Diagnostics, Vol. 22, Núm. 1, pp. 60-71

  2. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

  3. Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder

    Leukemia and Lymphoma

  4. Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients

    British Journal of Haematology, Vol. 189, Núm. 4, pp. 718-730

  5. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Blood Cancer Journal, Vol. 10, Núm. 2

  6. Reply to Brown et al: ‘Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis’

    Leukemia and Lymphoma

2019

  1. Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma

    Hematological Oncology

  2. Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas

    Blood Cancer Journal, Vol. 9, Núm. 7